News
NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)
2022-04-05 08:00
Asarina Pharma’s Annual General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting...
Asarina Pharma AB (publ) Year-end Report 2021 released
2022-02-24 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS TOURETTE SYNDROME The Capital Region of Denmark (Region Hovedstaden) was finally able to sign the clinical trial...
First patient in for landmark Tourette Syndrome study
2022-02-16 14:31
30 patients ranging from 12 to 45 years old will be taking part in a phase IIa proof-of-concept study at two major University Hospitals in Copenhagen -...
The phase IIa Tourette study will take place at the Danish National Center for Tourette at Herlev University Hospital, Scandinavia’s largest Tourette...
Asarina Pharma AB (publ) Q3 Report 2021 released
2021-11-25 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS Following an administrative delay from Region Hovedstaden (the Capital Region of Denmark) we expect to receive...
PMDD Phase IIb study, including post-hoc analysis showing ‘significant treatment effect’, published in Journal of Psychoneuroendocrinology
2021-09-28 12:30
Topline results for Asarina Pharma’s phase IIb study in Sepranolone for PMDD, released in April 2020, found that Sepranolone failed to meet its primary...
Administrative backlog at public authority causes short-term delay in Tourette study
2021-09-16 16:46
Asarina Pharma’s Clinical Trial Application for its phase IIa study in Tourette Syndrome was approved by the Danish Medical Agency in May 2021 and...
Asarina Pharma AB (publ) Q2 Report 2021 released
2021-08-19 08:00
FINANCIAL HIGHLIGHTS R&D HIGHLIGHTS MENSTRUAL MIGRAINE TOURETTE SYNDROME OCD For further information, please contact: Peter Nordkild, CEO Phone: +45...
CEO Peter Nordkild: “Obviously we had hoped for a different outcome. This solid clinical study unfortunately does not confirm the scientific hypothesis...
Asarina Pharma granted US patent for Sepranolone for Tourette syndrome, OCD and pathological gambling
2021-06-08 08:30
The new patent is valid until 2038. Tourette and OCD are common co-morbidities, both with strong compulsion mechanisms. In March 2021 Asarina Pharma shared...